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V. Abstract 
 
Background: Transverse myelitis (TM) is a term used to describe inflammation of 
the spinal cord. A small segment of the spinal cord is usually involved. However, 
when TM is severe enough to cause T2 weighted hyper-intensities extending across 
three or more vertebral segments on sagittal spinal magnetic resonance imaging 
(MRI), it is given the term: longitudinally extensive transverse myelitis (LETM). LETM 
is an infrequently encountered condition and the incidence of this syndrome is not 
well described. Recent studies show that the frequency of LETM ranges from 2 to 
10% of patients with TM. The causes of LETM can be broadly divided into 
demyelinating, autoimmune, infectious and miscellaneous. LETM is the most specific 
radiological finding of the neuromyelitis optica spectrum disorders (NMOSD) and has 
been extensively described in this condition. NMOSD has been typically found in 
human immunodeficiency virus (HIV) negative patients. Furthermore, LETM itself is 
not well described in HIV positive patients.  
Aims: Firstly, to describe the clinical characteristics and aetiology of patients with 
LETM in a South African setting. Secondly, to describe LETM in HIV positive 
patients. 
Methods: 22 Adult patients presenting with LETM to the division of Neurology of the 
University of the Witwatersrand were included in this prospective study. Patients 
were recruited from Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), 
Chris Hani Baragwanath Academic Hospital (CHBAH) and Helen Joseph Hospital 
(HJH). The study population were recruited over approximately 2 years. Results: The 
aetiology of LETM in this population was as follows: 15 patients were diagnosed as 
NMOSD, 4 patients had an infective cause, 1 had an ischaemic myelopathy and 2 
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had an unknown or idiopathic LETM. In terms of HIV status, 15 subjects were HIV 
negative and 7 were HIV positive. Of those that were HIV positive, 3 patients had 
tuberculous myelitis causing LETM and 4 met NMOSD diagnostic criteria. 
Conclusion: NMOSD is a common cause of LETM and is suggested by cervical 
involvement compared to a thoracic LETM which suggests non-NMOSD causes. In 
HIV positive patients with LETM, NMOSD is less likely and alternative diagnoses 
should be excluded, especially infective causes. Nevertheless, NMOSD occurs in 
HIV positive patients and may be associated with a high viral load. 
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X. Nomenclature 
 
AB  Antibody 
ADEM  Acute disseminated encephalomyelitis  
ANA  Antinuclear antibody  
AQP4  Aquaporin 4  
AZA  Azathioprine 
CBA  Cell based assay 
CD4  Cluster of differentiation 4 
CNS  Central nervous system  
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IVMP  Intravenous methylprednisolone 
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LETM  Longitudinally extensive transverse myelitis  
MOG  Myelin oligodendrocyte glycoprotein 
MRI  Magnetic resonance imaging  
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MS   Multiple Sclerosis 
NMO  Neuromyelitis optica  
NMOSD Neuromyelitis optica spectrum disorders 
PLEX  Plasma exchange 
SCD  Subacute combined degeneration of the spinal cord 
SDAF  Spinal dural arteriovenous fistula 
SS  Sjogren’s syndrome  
SLE  Systemic lupus erythematosus  
T1WI  T1-weighted image 
T2WI  T2-weighted image 
TB  Tuberculosis 
TBA  Tissue-based assay 
TM  Transverse myelitis 
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Chapter 1: Protocol and extended review of the literature 
 
1.1 Introduction 
Transverse myelitis (TM) is a term used to describe inflammation of the spinal cord. 
A small segment of the spinal cord is usually involved. Causes of TM include 
demyelinating conditions such as Multiple Sclerosis (MS), infections and systemic 
inflammatory auto-immune disorders. However, when TM is severe enough to cause 
T2 weighted hyperintensities extending across three or more vertebral segments on 
sagittal spinal magnetic resonance imaging (MRI), it is given the term: longitudinally 
extensive transverse myelitis (LETM).1 
 
LETM is an infrequently encountered condition and the incidence of this syndrome is 
not well described. Recent studies show that the frequency of LETM ranges from 2 
to 10% of patients with TM.2 These findings may be inaccurate, as patients with MS 
or neuromyelitis optica (NMO) were excluded, and the studies were of a small 
sample size. Furthermore, an accurate reflection of the prevalence of TM in general 
is also not well known. Thus, a true reflection of the incidence and prevalence of 
LETM is unknown, but there is a consensus within the literature that it is a condition 
which is becoming increasingly recognised. The causes of LETM can be broadly 
divided into demyelinating, infectious, miscellaneous and idiopathic. The 
miscellaneous category includes neuro-inflammatory, vascular, neoplastic-related 
and metabolic causes.   
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In order to guide appropriate and prompt investigations, it is imperative to recognise 
LETM early. A working diagnosis needs to be formulated quickly as this has major 
implications on the management and future outcome of the condition. If left 
undiagnosed and untreated, disastrous consequences may ensue.2 Thus, one has to 
be aware of LETM and its common causes. 
 
1.2 Demyelinating diseases and LETM 
The demyelinating causes of LETM include neuromyelitis optica spectrum disorders 
(NMOSD), MS and acute disseminated encephalomyelitis (ADEM). LETM is the 
most specific radiological finding of NMOSD.1,3 
 
1.2.1 Neuromyelitis optica spectrum disorders (NMOSD) 
1.2.1.1 Background 
NMO or Devic’s disease was first described in the late 19th century and is now a 
well-known cause of LETM. NMO is a severe central nervous system (CNS) 
demyelinating disorder involving characteristically, as the term neuromyelitis optica 
suggests, the optic nerves and spinal cord. Traditionally, Devic’s disease was used 
to describe patients with a monophasic illness consisting of acute or subacute 
bilateral optic neuritis, preceded or followed within days or weeks by a severe 
myelitis.1-3 Initially, lesions outside the optic nerves or spinal cord excluded the 
diagnosis of NMO.1  
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In 2004, Lennon et al reported on an NMO antibody (AB), which is more than 90% 
specific for NMO and is not found in patients with MS.1,4 The target antigen of this 
AB was subsequently found to be aquaporin 4 (AQP4), the predominant water 
channel of the CNS, located in astrocytic foot processes at the blood-brain barrier.5 
The detection of this AB and additional studies revealed that patients with NMO may 
have cerebral lesion/s, which are often clinically silent, and more importantly are not 
in keeping with MS.1 Thus, the 2006 diagnostic criteria for NMO required 1) optic 
neuritis, 2) myelitis, and 3) at least two of three supportive criteria: a) MRI evidence 
of a contiguous spinal cord lesion extending over 3 or more segments in length 
(LETM), b) onset brain MRI non-diagnostic for multiple sclerosis, or c) NMO-antibody 
seropositivity.1 This combination of diagnostic criteria were found to be 99% 
sensitive and 90% specific for NMO.1 
 
Since the discovery of the specific NMO AB, patients have been identified with 
isolated optic neuritis or LETM, with positive AQP4-AB.6 The 2006 diagnostic criteria 
for NMO did not include these patients with initial features of NMO or NMO variants. 
In 2007, these conditions became collectively known as the neuromyelitis optica 
spectrum disorders (NMOSD).6 NMOSD included patients with isolated optic neuritis 
or LETM with AQP4-AB, recurrent myelitis, or recurrent isolated optic neuritis.1,6 The 
NMOSD were at that time, unified by the presence of AQP4-AB.4,5 Further advances 
in the AQ4-AB allowed detection and improvement on the spectrum of non-
opticospinal characteristics of NMO.3 These findings rendered the 2006 criteria 
inadequate for current use.3 
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1.2.1.2 Current diagnostic Criteria for NMOSD 
Almost a decade later, in 2015, the International Panel for NMO Diagnosis (IPND) 
proposed updated diagnostic criteria in order to incorporate the NMOSD.3 Two major 
points were outlined. Firstly, NMO and its related spectrum disorders would both be 
incorporated into the umbrella term NMOSD.3 The reason for this is that the 
conditions are similar in terms of clinical behaviour, immunopathology and 
treatment.3  Furthermore, patients with incomplete forms of NMO may later develop 
the “classical” syndrome.3 The historically significant term NMO would be entrenched 
into the new title NMOSD as most patients, despite non-opticospinal manifestations, 
eventually develop  typical opticospinal disease.3 Secondly, the international 
consensus diagnostic criteria would be based on combining clinical, radiological and 
serological testing.3  
 
The criteria divide diagnosis of NMOSD into two groups; NMOSD with AQP4-
Immunoglobulin G (IgG) and, NMOSD without AQP4-IgG or where AQ4-IgG status is 
unknown.3 In the AQ4-IgG positive group, at least one of six core clinical 
characteristics needs to be met in order to make the diagnosis.3 The core clinical 
characteristics consist of the following CNS regions: 1) optic nerves, 2) spinal cord, 
3) area postrema of the dorsal medulla, 4) brainstem, 5) diencephalon, and 6) 
cerebrum.3    
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Table I: NMOSD diagnostic criteria for adult patients32 
 
 
A few clinical syndromes implicating the optic nerves, spinal cord and area postrema 
are particularly suggestive of NMOSD.3 These include; optic neuritis that is 
simultaneously bilateral, involves the chiasm or more than half of the optic nerve 
length, causes an altitudinal visual field defect, or causes severe residual visual 
loss.3 Other features are a complete (rather than partial) myelopathy, and an area 
postrema syndrome causing intractable hiccups or nausea and vomiting.3 
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In the AQ4-IgG negative or unknown group, two or more core clinical characteristics 
need to occur with dissemination in space.3 At least one of these needs to be one of 
the three most common NMOSD features: optic neuritis, symptomatic LETM or an 
area postrema syndrome with associated medullary MRI lesion.3 Where applicable, 
additional MRI requirements are also necessary for this diagnostic group (Table 1).3 
The two core features may occur with a single attack or multiple attacks.3 Thus, 
making the diagnosis in this AQ4-IgG negative/unknown group is more challenging 
as more features need to be detected with additional caveats. However, it allows a 
positive diagnosis of NMOSD to be made in the absence of AQ4-IgG. This is of great 
benefit in situations where AQ4-Ab is not available or initially negative. 
 
The panel further concluded that a diagnosis of NMOSD cannot be made in patients 
with isolated asymptomatic AQ4-IgG positivity or asymptomatic compatible MRI 
lesions, as at least one symptomatic clinical attack is necessary.3 The clinical course 
of asymptomatic patients with either positive serology or neuro-imaging is not well 
known.3 Also, diagnostic criteria are not met if a single feature is present in the 
absence of AQ4-IgG as there is no single pathognomonic core characteristic of 
NMOSD.3 Similarly, no single feature excludes the diagnosis.3 However, there are 
“red flags” that may suggest an alternative diagnosis (Table 2).3 
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Table II: Red flags: Findings atypical for NMOSD33 
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1.2.1.3 Epidemiology 
A review of population based studies in Europe, South Asia, the Caribbean and 
Cuba reveal that the incidence of NMOSD varies between 0, 05-4 per 100 000 and 
the prevalence ranges from 0,5-4 per 100 000.7 Mean age at onset was found to be 
between 33 to 46 years but NMOSD has been described in paediatric cases and 
older adults.7 66-88% of NMOSD are estimated to be female, which is in keeping 
with female dominance in auto-immune diseases.7 In relapsing NMOSD, female 
prevalence is approximately 80% compared to an almost equal gender distribution in 
monophasic disease.7 
 
NMOSD may have a higher prevalence in the black population; however this may be 
over-estimated due to the lower incidence of MS in this race group.8,9 Ethnicity has 
also been shown to affect clinical phenotype and outcome.7 Due to the uncommon 
occurrence of NMOSD and most of the epidemiological data being documented prior 
to the revised 2015 diagnostic criteria, the true demographics of this disorder is not 
well known.    
 
1.2.1.4 LETM in NMOSD 
As stated earlier, LETM is the most specific finding of NMOSD, and is less common 
in other demyelinating diseases.1,3 The LETM lesion in NMOSD is characterised by a 
hypointensity on T1-weighted images (T1WI), a hyperintensity on T2-weighted 
images (T2WI), may enhance after gadolinium administration, typically involves the 
central grey matter and may cause cord swelling.3,10 The cervical and upper thoracic 
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cord is more commonly affected in NMOSD.10 Another distinct characteristic of 
cervical LETM in NMOSD is the extension of the lesion into the medulla.3,10  
 
The LETM lesion in this spectrum of disorders tends to fragment into smaller lesions 
after treatment with steroids and during remission.10 Additionally, recurrent attacks of 
myelitis may lead to spinal cord atrohy.10 This emphasises the importance of 
obtaining spinal cord imaging early during the presentation of a myelopathy as it may 
be missed if the MRI is done later in the course of the disease. 
 
1.2.1.5 NMOSD Antibodies 
The discovery of AQ4-AB revolutionised the diagnosis of NMOSD as it allowed this 
condition to be considered as a distinct demyelinating disorder. This antibody was 
first included in the 2006 diagnostic criteria due to its high specificity in diagnosing 
NMO and distinguishing it from MS.1 As already mentioned, AQ4-AB detection 
allowed for the broadening of the phenotype of NMOSD and lead to the current 2015 
diagnostic criteria.3 
 
Although patients with LETM may meet NMOSD criteria irrespective of AQ4-AB 
status, there are some observed differences based on the AQ4-AB status. There is a 
greater chance of relapse in patients with LETM who are positive for AQ4-AB and 
this is estimated to be about 60% within 1 year of initial LETM.3,11 LETM and AQ4-AB 
negative patients are more commonly associated with a monophasic disorder.3,11 In 
a study of 76 LETM patients, Kitley et al (2013) found a higher proportion of females, 
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especially women older than 45 years of age, in those that were AQ4-AB positive, 
versus younger males (less than 35 years) with more common involvement of the 
conus in those that were AQ4-AB negative.12 Furthermore, positive AQ4-AB status is 
strongly associated with systemic auto-immune disorders.3,12 
    
The sensitivity and specificity of the AQ4-AB differs depending on which assay is 
used. Based on a recent meta-analysis, the approximate sensitivity for the cell based 
assay (CBA) is the highest at 76% whereas the tissue-based assay (TBA) and the 
enzyme-linked immunosorbent assay (ELISA) test were 59% and 65% 
respectively.13 The mean specificity of all 3 tests were between 97-99%.13 This is 
extremely beneficial as there in minimal doubt to the diagnosis when the test is 
positive. However, it may be challenging when the test is negative as the lower 
sensitivity may yield false negative results. A further challenge is that the CBA is not 
easily available and thus negative results from less sensitive tests do not exclude the 
diagnosis. 
 
Retesting of a suspected false negative result should be during an acute attack or 
relapse and, if possible, before immunotherapies are instituted or during a treatment-
free period or with a more sensitive test.3,14 This is due to the observation that 
antibody levels are highest during relapses and are reduced with 
immunosuppressive therapy.3,14  
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Between 10-30% of NMOSD patients remain AQ4-AB negative despite the most 
sensitive cell based assays.15 Some of these patients have been shown to have 
antibodies targeting myelin oligodendrocyte glycoprotein (MOG).3,15 Some features 
of MOG-AB positive NMOSD included a less female dominance, younger age and 
was more associated with optic neuritis (versus myelitis), caudal myelitis, 
monophasic attacks and better recovery.3,15 Some of these features are strikingly 
similar to the phenotype observed in AQ4-AB negative cases and thus MOG 
antibodies may be responsible for this group of patients. This suggests that there 
may be an alternative pathogenesis in these patients, yet this remains to be 
determined.3 
 
1.2.1.6 NMOSD and systemic autoimmune disease overlap 
There is a strong association between LETM and non-organ specific systemic 
autoimmune conditions, especially Sjogren’s syndrome (SS) and systemic lupus 
erythematosus (SLE).16,17 In a large study of NMOSD, 47% of patients were found to 
have positive antinuclear antibody (ANA) or extractable nuclear antigen (ENA) 
antibodies, with 3% fulfilling clinical diagnostic criteria for SLE or SS.16 Interestingly, 
AQ4-AB were not found in any patients with SLE or SS who did not have clinical 
features of NMOSD and this finding was reproduced in other similar studies.16-18 
Thus, the presence of AQP4-AB with LETM in the clinical context of SLE or SS likely 
represent the coexistence of two autoimmune conditions rather than LETM being the 
complication of SLE/SS.16,17 
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NMOSD has also been associated with other autoimmune diseases such as thyroid 
disease, myasthenia gravis and celiac disease.3,18 These autoimmune diseases are 
not known to cause destructive CNS pathology and thus further emphasizes the 
point that NMOSD may coexist with systemic autoimmune disease.18 
 
From a practical point of view, any patient presenting with LETM should be tested for 
AQ4-AB and investigated to meet NMOSD diagnostic criteria, regardless of possible 
or known rheumatological disease.3,18 If other autoimmune antibodies are found in 
the presence of LETM, a co-existing rheumatological or autoimmune disease should 
be pursued based on the clinical presentation.3,18 The presence of LETM and a 
rheumatological diagnosis actually favours the concurrent diagnosis of NMOSD, and 
LETM should not be considered due to the rheumatological disease itself.3,18 
 
1.2.1.7 Human immunodeficiency virus (HIV) and NMOSD 
The co-occurrence of human immunodeficiency virus (HIV) and NMOSD is 
uncommon and the literature regarding this association consists predominantly of 
case reports.19-22  At the time of clinical presentation of these reported cases, some 
were receiving highly active antiretroviral therapy (HAART) and the cluster of 
differentiation 4 (CD4) counts and HIV viral loads were variable.19-22 Almost all 
received intravenous (IV) steroids and a few received long term immunosuppression 
with inconsistent responses.19-22 Prior to 2017, only 3 patients were documented to 
be both HIV and AQ4-AB positive.20-22 
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A recently published review of NMOSD patients in the Kwa-Zulu Natal province of 
South Africa revealed the largest documented number of HIV positive patients with 
NMOSD.23 A retrospective review was performed over 9 years and 12 HIV positive 
patients with a NMOSD presentation were identified.23 Of the 10 HIV positive 
patients that were tested for AQ4-AB, 4 were dual HIV and AQ4-AB positive.23 As 
this was a retrospective review, it is uncertain if the HIV seroconversion in these 
patients occurred prior or subsequent to their NMOSD presentation.23 
 
Considering the HIV epidemic in South Africa, co-existence with NMOSD seems to 
be unusual. However, in the correct clinical context, both diagnoses may occur. Due 
to the scarcity of literature, there is no evidence to guide treatment in these rare 
instances. Balancing immunosuppression in an already immunocompromised patient 
may pose a therapeutic dilemma.  
 
1.2.1.8 Treatment of NMOSD 
Treatment of NMOSD is aimed at reducing AQ-4 AB induced central nervous system 
inflammation. 24 Disability is dependent on the severity and number of attacks.24,25 
Goals of therapy are therefore directed at reducing attack severity and preventing 
future attacks.24,25 The specific therapeutic options include immunosuppression, B-
cell depleting agents and plasma exchange (PLEX).24,25 
 
There are no prospective randomised controlled trials to guide therapy and thus 
treatment guidelines are based on case studies and expert opinion.24,25 Intravenous 
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methylprednisolone (IVMP) at a dose of 1000mg per day for at least 3 to 5 days is 
the recommended guideline for initial treatment of an acute attack of NMOSD.24,25 If 
there is no significant improvement after IVMP, 5 cycles of PLEX should be 
considered in an attempt to aid recovery.24,25 Intravenous cyclophosphamide or 
intravenous immunoglobulin (IVIG) may be of benefit in acute refractory cases.24,25     
 
Low dose oral prednisolone and PLEX may be used long-term as preventative 
therapy.24 Prednisolone also serves as a bridge between acute and preventative 
treatment and can be used as an adjunct if dual preventative therapy is required.25 
Due to the high side effect profile of long term prednisolone use, steroid-sparing 
agents are typically instituted.24,25  Azathioprine (AZA), mycophenolate mofetil and 
rituximab are generally recommended as 1st line preventative agents whereas 
mitoxantrone and methotrexate are reserved for refractory cases.24,25 The selection 
of long term immunosuppression should be based on patient side effect profile, 
comorbidities, availability, cost and physician’s familiarity with the use of the 
agent.24,25 To re-emphasize, there is no class I evidence available to direct therapy in 
NMOSD and thus optimal dosages and duration of treatment is unknown.24,25  
However, based on case series and expert opinion, these agents seem to be 
moderately to highly effective.24,25 
      
Immunomodulatory drugs used in the treatment of MS may adversely affect outcome 
in NMOSD and thus need to be avoided.24,25 Interferon beta, natalizumab and 
fingolimod have been shown to worsen disease activity in NMOSD.24 Thus, 
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differentiating between NMOSD and MS is essential in order to select appropriate 
treatment. 
  
1.2.2 LETM in MS 
Unlike LETM in NMOSD, spinal cord lesions in MS tend to be shorter (two or less 
spinal segments) and predominantly involve lateral and dorsal white matter 
asymmetrically within the cord.2,3,26 Chronic or progressive MS may produce 
coalescent cord lesions that appear as indistinct hyper-intensities on MRI and may 
mimic a LETM.3,26  However, there have been reports of LETM occurring in adult MS 
patients at an estimated frequency of about 3%.2,27 In contrast to NMOSD, LETM in 
MS may be shorter (4,5 versus 7,1 vertebral lengths) and is less likely to be 
associated with cord expansion, hypointensity on T1WI or gadolinium 
enhancement.2 Up to 15% of relapsing remitting MS in children may have a LETM.2,3 
 
Within the previously termed “optico-spinal variant of MS”, the frequency of LETM 
was found to be much higher, up to 59%.2,27 However, according to the new NMOSD 
diagnostic criteria, these patients most likely represent NMOSD and thus should no 
longer be considered a variant of MS.3  
 
Brain imaging in a patient with LETM may aid in differentiating typical MS or NMOSD 
features.3,26 Typical areas of involvement in MS include peri-ventricular, juxtacortical, 
infratentorial and spinal cord.26 The revised 2010 McDonald criteria should be used 
in a patient suspected of having MS and these criteria need to be excluded if a 
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diagnosis of NMOSD is made.3,26 As eluded to earlier, this differentiation is vital to 
guide therapy.   
 
1.2.3 LETM in ADEM 
ADEM is characterised by encephalopathy, large multifocal areas of cerebral 
demyelination and may involve small segments of the spinal cord.26 In a minority of 
adult patients, ADEM has also been reported to cause spinal cord lesions which are 
longer than two vertebral segments.2 In paediatric ADEM, LETM has been reported 
in up to 90% of cases.2,26 Thus, paediatric LETM is less specific for NMOSD and 
occurs with a higher frequency in ADEM and MS.3 
 
A preceding infection occurs in the majority of patients with ADEM.2 Therefore, an 
infection may infrequently cause LETM via the induction of ADEM.2 However, 
infections are more likely to result in LETM directly.2    
 
1.3 Infective causes of LETM 
About 10% of TM constitute infectious or para-infectious causes which, almost 
always, present with clinical and cerebrospinal fluid (CSF) features of meningitis.26 
Infectious agents that have been reported to directly cause LETM include syphilis, 
Human T-lymphotropic virus 1 (HTLV1), CNS tuberculosis (TB) and parasitic 
infections such as Schistosomiasis, Toxocara canis and Ascaris Suum.2,26,27 Hence, 
features of meningitis in the presence of LETM should prompt urgent investigation to 
diagnose a suspected infection and expedite specific therapy.  
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Infections may also indirectly cause LETM by activating ADEM or NMOSD.2 The 
infectious agents documented to induce NMOSD consist of varicella zoster virus, 
cytomegalovirus, Epstein Barr virus, HIV, dengue, hepatitis A, mycoplasma 
pneumonia and TB.2 Thus, the presence of a specific infection does not always 
implicate the infection as the cause of a LETM and a diagnosis of NMOSD or ADEM 
should be considered in the correct clinical context.2  
 
1.3.1 TB and LETM 
About 1% of all TB cases constitute CNS TB, of which approximately half involves 
the spine.28 It is estimated that 7% of patients with spinal TB have intramedullary 
lesions in the form of radiculomyelitis, TM, intraspinal granulomas and thrombosis of 
the anterior spinal artery.28 LETM is very rarely a complication of TB myelitis but 
several cases have been described.26,28 One needs to also consider that a syrinx or 
intraspinal tuberculoma, which may complicate TB meningitis/myelitis, may produce 
an intraspinal hyperintensity on T2WI but these have different characteristics to a 
typical LETM.26,28  
 
Interestingly, pulmonary TB has been associated with NMOSD by a number of case 
reports.2,28 The proposed mechanism is an immune-mediated inflammatory 
demyelination initiated by pulmonary TB. 28 Therefore, pulmonary TB may lead to a 
LETM via activation of NMOSD or CNS TB may lead to a LETM. Both of these 
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mechanisms need to be considered in any patient with a LETM and suspected TB, 
especially due to the increased incidence of TB in a high HIV setting. 
 
1.3.2 HIV and LETM 
To recapitulate, HIV has been suggested to possibly trigger NMOSD, or HIV could 
predispose to opportunistic infections which could cause LETM or may also trigger 
NMOSD.2,27,28 The potential mechanisms of HIV causing LETM indirectly have been 
discussed yet there is a lack of evidence within the literature that HIV may cause 
LETM directly. 
 
HIV-associated vacuolar myelopathy  is a well described syndrome and has been 
found in up to a third of some post mortem series.27 Radiological studies describing 
spinal cord MRI findings in patients with HIV have revealed predominantly cord 
atrophy, with or without signal changes.27,29 These atrophic lesions may be 
longitudinally extensive but none were shown to cause cord expansion or enhance 
with contrast.27,29 Vacuolar myelopathy may cause an atrophic cord with signal 
change that possibly meets the LETM definition. However, a diagnosis of LETM due 
to HIV-associated vacuolar myelopathy needs to be made with caution and by 
exclusion, as there are more likely causes, especially if the clinical presentation is 
not chronic.      
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1.4 Miscellaneous causes of LETM 
1.4.1 Neuro-inflammatory  
1.4.1.1 Neurosarcoidosis 
Neurosarcoidosis is an inflammatory granulomatous disease and accounts for 5-10% 
of systemic sarcoidosis.26,27 The spinal cord is affected in only 0, 3% of sarcoidosis.26 
Intramedullary spinal cord lesions are generally iso-intense on T1WI, variable on 
T2WI, enhance with gadolinium and may cause cord expansion.26 Myeloradicular 
enhancement with a LETM, in the context of respiratory disease, could favour a 
diagnosis of neurosarcoidosis.26 A definitive diagnosis is made by biopsy of the CNS 
or systemic lesion.26,27 
 
1.4.1.2 Neuro-Behcet’s disease 
Behcet’s disease is a vasculitic disorder characterised by systemic features such as 
apthous and genital ulcers, uveitis, iritis and pathergy.27,30 The occurrence of neuro-
Behcet’s varies between 5-50% of patients and is well described.27 Spinal cord 
involvement is reported in up to 14% of Behcet’s disease and when myelitis does 
occur, it tends to be longitudinally extensive and involve both gray and white 
matter.27 Diagnosis of Behcet’s disease is based on clinical criteria.27  
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1.4.2 Vascular 
1.4.2.1 Spinal cord infarction 
Spinal cord infarction develops within minutes, accounts for about 1% of all strokes 
and is most commonly due to occlusion of the anterior spinal artery.26,27 Spinal or 
aortic vascular surgery, dissection of an aortic aneurysm or vertebral artery, 
hypotension, vasculitis or atherosclerosis may predispose to ischaemia of the spinal 
cord.26,27 In the acute to subacute stage, ischaemia produces a longitudinally 
extensive hyperintensity on T2WI, may enhance post contrast, could result in cord 
enlargement and restricted diffusion is seen on diffusion-weighted imaging (DWI).26 
In the chronic stage, the classical MRI finding of “snake eyes” (T2-weighted 
hyperintesities in the ventral grey matter with sparing of the dorsal horns on axial 
images) is usually seen.26 Ischaemic lesions  may be distinguished by its tendency to 
affect specific areas of the cord, such as C1 to C3, C4 to C7, T3 to T7 and T8 to 
conus.2  
 
1.4.2.2 Spinal dural arteriovenous fistula  
Spinal dural arteriovenous fistulae (SDAF) are the most common type of spinal 
vascular malformations and lead to spinal venous congestion.26 SDAF typically 
causes a chronic thoracic myelopathy, usually in elderly males and may be 
exacerbated by movement or the valsalva manoeuvre.2 Venous hypertension results 
in cord oedema which is detected on MRI as a longitudinally extensive T2 
hyperintensity.2,26 The specificity of SDAF is increased if flow voids are present 
which indicate dilated intradural veins.2,26 The gold standard for SDAF diagnosis is 
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spinal angiography and therapy such as embolization may be instituted at the same 
setting.26,27 
 
1.4.3 Neoplastic - related 
1.4.3.1 Intramedullary Spinal Cord Tumours  
Most spinal tumours are extramedullary with metastatic disease being the most 
common.26 Intramedullary spinal cord tumours are rare and consist largely of 
ependymomas and astrocytomas.2,26 These tumours tend to present insidiously and 
radiologically appear hypo-isointense on T1WI, hyperintense on T2WI, extend 
across multiple segments and cause focal enlargement of the spinal cord.2,26 
Ependymomas avidly enhance post contrast whereas astrocytomas partially 
enhance.26 
  
1.4.3.2 Paraneoplastic phenomenon 
Paraneoplastic myelopathy is a well-described yet rare entity.2 In some studies of 
paraneoplastic myelopathies, between 42-47% had LETM.2,30 The most common 
antibodies found in paraneoplastic LETM include anti-collapsin response-mediator 
protein-5 (CRMP-5) and anti-amphiphysin.2,30 These antibodies are both associated 
with small cell carcinoma of the lung and anti-amphiphysin is also associated with 
breast cancer.2 Paraneoplastic LETM, in the absence of antibodies, has also been 
found in lymphoma, oesophageal and thyroid cancer.2  
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There have been suggestions that NMOSD may occur as a paraneoplastic 
phenomenon.2,23 However, the current NMOSD diagnostic guidelines consider an 
underlying malignancy as an atypical feature or red flag for NMOSD.3 Therefore, a 
LETM should be considered as paraneoplastic if found in the context of a 
malignancy and a neoplastic screen should be performed in any unexplained LETM. 
 
1.4.3.3 Radiation myelopathy 
Delayed post-radiation demyelination of the spinal cord might occur after treatment 
for throat, neck, mediastinal and thoracic tumours.2,26 The LETM lesions usually 
develop 1-2 years post-radiation and may be associated with cord expansion and 
enhancement.26,27 Chronic lesions show spinal cord atrophy.26,27 A radiological clue 
to this diagnosis is the hyperintense signal change in the adjacent vertebral bodies 
on T1WI.26 A specific history of previous radiation exposure is thus necessary in any 
LETM patient.   
 
1.4.4 Metabolic 
LETM may be caused by subacute combined degeneration of the spinal cord (SCD) 
due to vitamin B12 deficiency.2,26 Copper deficiency is another cause of LETM and 
may occur in isolation or with SCD.2,26 Both of these deficiency states produce 
similar clinical and radiological findings of a subacute to chronic dorsolateral spinal 
cord syndrome.2,26 The LETM typically involves the posterior and lateral columns.2,26 
It is vital to check for vitamin B12 and copper levels in the setting of LETM as these 
deficiencies are potentially reversible.  
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1.5 Idiopathic LETM 
In a study of 108 patients with isolated LETM, 42 were classified as having idiopathic 
sero-negative LETM.31 AQ4-AB negative status was confirmed by using 3 different 
assays and MOG-AB was also tested.31 Infectious, vascular, neoplastic, post 
radiation and metabolic causes of the LETM were excluded.31 Unlike NMOSD, these 
patients had different clinical features such as male predominance, older age at 
onset and milder syndromes.31 This suggests that this group of patients may 
represent a separate disease entity with a possible distinctive underlying 
pathophysiology.  
 
 
1.6 Motivation for research study  
Patients with LETM are not an uncommon presentation to our Neurology division. 
With the availability of MRI facilities and resources to detect AQP4-AB, patients can 
be efficiently assessed for NMOSD. Other diagnoses can also be explored with 
appropriate investigations.  In our HIV epidemic setting, there is an opportunity to 
evaluate patients presenting with LETM and explore the possible interplay between 
HIV and LETM. To my knowledge, this will be the first research study specifically 
investigating LETM in South Africa.  
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Aim 
The aim of this study is to describe the clinical profile of patients with longitudinally 
extensive transverse myelitis (LETM) 
 
Study Objectives 
1. Primary Objectives 
a) To describe the study population 
b) To describe the spectrum of disease causing LETM that is AQ4-Ab 
negative 
c) To develop a clinical diagnostic approach to patients with LETM in a South 
African setting  
 
2. Secondary Objectives 
a) To compare AQ4-Ab positive and negative patients with LETM 
b) To compare HIV positive and negative patients with LETM 
c) To describe a relationship between AQP4-Ab and HIV in LETM patients  
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Methods 
1. Study Design 
 Prospective study 
2. Study Setting 
The Neurology Division of the Department of Neurosciences, University 
of the Witwatersrand. Patients presenting to Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH), Chris Hani Baragwanath 
Academic Hospital (CHBAH) and Helen Joseph Hospital (HJH) will be 
used. 
3. Study population 
a) Inclusion Criteria 
i. All adult patients presenting with LETM 
b) Exclusion Criteria 
i. Children with LETM 
ii. Patients meeting the definition of LETM due to trauma 
iii. Patients meeting the definition of LETM secondary to spinal 
column pathology 
4. Sampling Method 
A convenience sampling method will be used 
5. Sampling Size 
A minimum of 10 patients with LETM meeting inclusion and exclusion 
criteria will be used 
6. Sample Selection 
Patients presenting with LETM from the 1st of March 2015 to 31st of 
December 2016 will be used 
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7. Measurement Instruments/Tools 
Collection of data will be done by using a data collection sheet (see 
Appendix C) 
8. Investigations – all investigations performed are routine in any patient 
presenting with a myelopathy, and no additional investigations will be 
requested for the study. 
a) The following investigations will be performed on all patients: 
- Full blood count (FBC) 
- Urea & electrolytes (UE) 
- Calcium, magnesium, phosphate (CMP) 
- Liver function tests (LFT) 
- HIV 
- C-reactive protein (CRP)  
- Erythrocyte sedimentation rate (ESR)  
- Serum angiotensin converting enzyme (S- ACE) 
- Syphilis 
- Full Autoimmune screen 
- Vitamin B12 level 
- Serum Copper and caeruloplasmin level 
- Thyroid stimulating hormone (TSH) 
- Cerebrospinal fluid analysis 
- MRI brain and spinal cord 
- AQP4-Ab (in patients with LETM on MRI) 
b) Other specific investigations will be performed if clinically indicated on 
an individual patient basis 
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9. Data Analysis 
a) Data will be captured using an excel spreadsheet 
b) This will be achieved using a descriptive clinical analysis 
10. Ethics 
a) The protocol will be submitted for ethics approval to the Human Research 
Ethical Committee of the University of the Witwatersrand 
b) Consent will be obtained from each patient used in the study 
c) Data confidentiality: Each data sheet (see Appendix C) will be assigned a 
study number only. Neither patient names nor hospital numbers will be 
recorded. Any association between the study numbers, patient initials and 
identity of patients will be kept separate.  
11. Study Strengths 
a) The first study to describe LETM patients in South Africa 
b) The first study to evaluate a potential relationship between HIV and LETM 
c) The first study to evaluate a potential relationship between HIV and AQP4-
Ab 
d) The data will be collected from a single researcher only. This will ensure 
that the data is collected in a standardised manner and is reliable. The use 
of data collection sheets, will standardise the data collection process 
12. Study Limitations  
a) Selection Sampling Bias:   
The study population only includes patients presenting to the Neurology 
division of the University of the Witwatersrand, and thus the sample is not 
a true representative of the entire population 
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b) Sample size: 
The small sample size will limit the validity of results 
13. Funding 
The funding of this audit, if required, will be provided by the doctor 
conducting the audit. No extra cost will be imposed on the hospital or 
the patient. In essence the study will be self-funded 
 
14. Timing 
The study will commence once approval is received. The audits 
expected duration is approximately 30 months. Depending upon clinical 
commitments of the primary investigator, the audit time frame may be 
shorter or longer 
 
The following Gantt chart shows the estimated timeline of the study: 
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Chapter 2: Proposed Manuscript 
Background 
Introduction 
Transverse myelitis (TM) is a term used to describe inflammation of the spinal cord. 
A small segment of the spinal cord is usually involved. However, when TM is severe 
enough to cause T2 weighted hyperintensities extending across 3 or more vertebral 
segments on sagittal spinal magnetic resonance imaging (MRI), it is given the term: 
longitudinally extensive transverse myelitis (LETM).1 
LETM is an infrequently encountered condition and the incidence of this radiological 
syndrome is not well described. Studies show that the frequency of LETM ranges 
from 2-10% of patients with TM.2 The causes of LETM can be broadly divided into 
demyelinating, infectious, miscellaneous and idiopathic. The miscellaneous category 
includes neuro-inflammatory, vascular, neoplastic-related and metabolic causes. 
Neuromyelitis Optica Spectrum Disorders (NMOSD) 
The demyelinating causes of LETM include neuromyelitis optica spectrum disorders 
(NMOSD), multiple sclerosis (MS) and acute disseminated encephalomyelitis 
(ADEM). LETM is the most specific radiological finding of NMOSD and is much less 
common in MS and ADEM.1-3 The LETM lesion in NMOSD is characterised by a 
hypointensity on T1-weighted images (T1WI), a hyperintensity on T2-weighted 
images (T2WI), may enhance after gadolinium administration, typically involves the 
central grey matter and may cause cord swelling.3,4 The cervical and upper thoracic 
cord is more commonly affected in NMOSD.4 Another distinct characteristic of 
cervical LETM in NMOSD is the extension of the lesion into the medulla.3,4  
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LETM is 1 of 6 core characteristics of NMOSD, and thus only requires a positive 
aquaporin 4 -antibody (AQ4-AB) to confirm the diagnosis of NMOSD.3 If the AQ4-AB 
is negative (or is not available) then 2 core clinical features need to be present in 
order to meet NMOSD diagnosis.3 Making the diagnosis in this AQ4-IgG 
negative/unknown group is more challenging as more features need to be detected, 
however, it allows a positive diagnosis of NMOSD to be made in the absence of 
AQ4-IgG. This is of great benefit in situations where AQ4-Ab is not available or 
initially negative. 
A review of population based studies in Europe, South Asia, the Caribbean and 
Cuba reveal that the incidence of NMOSD varies between 0, 05-4 per 100 000 and 
the prevalence ranges from 0,5-4 per 100 000.5 NMOSD may have a higher 
prevalence in the black population; however this may be over-estimated due to the 
lower incidence of MS in this race group.6,7 Due to the uncommon occurrence of 
NMOSD and most of the epidemiological data being documented prior to the revised 
2015 diagnostic criteria, the true demographics of this disorder is not well known.    
Human Immunodeficiency Virus (HIV) and NMOSD 
The co-occurrence of human immunodeficiency virus (HIV) and NMOSD is 
uncommon and the literature regarding this association consists predominantly of 
case reports.8-11 Prior to 2017, only 3 patients were documented to be both HIV and 
AQ4-AB positive.9-11 However, a recent retrospective  review of NMOSD patients in 
the Kwa-Zulu Natal province of South Africa revealed 12 HIV positive patients with 
NMOSD, 4 of which were dual HIV and AQ4-AB positive.12 As this was a 
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retrospective review, it is uncertain if the HIV seroconversion in these patients 
occurred prior or subsequent to their NMOSD presentation.12 
Considering the HIV epidemic in South Africa, co-existence with NMOSD seems to 
be unusual. Due to the scarcity of literature, there is no evidence to guide treatment 
in these rare instances. Balancing immunosuppression in an already 
immunocompromised patient may pose a therapeutic dilemma.  
Infections and LETM 
Infectious agents have been reported to directly cause LETM such as syphilis, 
Human T-lymphotropic virus 1 (HTLV1), CNS tuberculosis (TB) and parasitic 
infections.2,13,14 Hence, features of meningitis in the presence of LETM should 
prompt urgent investigation to diagnose a suspected infection and expedite specific 
therapy.  
Infections may also indirectly cause LETM by activating ADEM or NMOSD.2 The 
infectious agents documented to induce NMOSD consist of varicella zoster virus, 
cytomegalovirus, Epstein Barr virus, HIV, dengue, hepatitis A, mycoplasma 
pneumonia and TB.2 Thus, the presence of a specific infection does not always 
implicate the infection as the cause of a LETM and a diagnosis of NMOSD or ADEM 
should be considered in clinical context.2  
LETM is very rarely a complication of TB myelitis but several cases have been 
described.13,15 Interestingly, pulmonary TB has been associated with NMOSD by a 
number of case reports.2,15 The proposed mechanism is an immune-mediated 
inflammatory demyelination initiated by pulmonary TB.15 Therefore, pulmonary TB 
may lead to a LETM via activation of NMOSD or CNS TB may lead to a LETM. Both 
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of these mechanisms need to be considered in any patient with a LETM and 
suspected TB, especially due to the increased incidence of TB in a high HIV setting. 
HIV has been suggested to possibly trigger NMOSD, or HIV could predispose to 
opportunistic infections which could cause LETM or may also trigger NMOSD.2,14,15 
However, there is a lack of evidence within the literature that HIV may cause LETM 
directly. HIV-associated vacuolar myelopathy is a well described syndrome which 
may cause an atrophic cord with signal change that possibly meets the LETM 
definition.14,16 However, a diagnosis of LETM due to HIV-associated vacuolar 
myelopathy needs to be made with caution and by exclusion, as there are other 
possible causes, especially if the clinical presentation is not chronic.      
Motivation for research study 
In order to guide appropriate and prompt investigations, it is imperative to recognise 
LETM early. A working diagnosis needs to be formulated quickly as this has major 
implications on the management and future outcome of the condition. Patients with 
LETM are not an uncommon presentation to our Neurology division. With the 
availability of MRI facilities and resources to detect AQP4-AB, patients can be 
efficiently assessed for NMOSD. Other diagnoses can also be explored with 
appropriate investigations.  In our HIV epidemic setting, there is an opportunity to 
evaluate patients presenting with LETM and explore the possible interplay between 
HIV and LETM. To my knowledge, this will be the first research study specifically 
investigating LETM in South Africa. 
Aims: i.) To describe the clinical characteristics and aetiology of patients 
with LETM in a South African setting  
ii.) To describe LETM in HIV positive patients 
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Methods 
 22 Adult patients presenting with LETM to the division of Neurology of the University 
of the Witwatersrand in Johannesburg, South Africa, were included in this 
prospective study. Patients were recruited from Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH), Chris Hani Baragwanath Academic Hospital (CHBAH) 
and Helen Joseph Hospital (HJH). The study population were recruited and 
monitored over approximately 2 years (July 2015 to March 2017). Clinical, 
laboratory, radiological and other ancillary investigations were used to determine the 
cause of the LETM in each patient. Treatment modalities and response were 
recorded. Extended Disability Status Scale (EDSS) scores were determined at LETM 
onset, best EDSS post-treatment and outcome EDSS at final follow-up. Information 
was initially recorded on a standardised data collection sheet and then captured on 
an excel spreadsheet. The study was approved by the University of Witwatersrand 
Human Research Ethics Committee.  
Statistical analysis  
Stata (version 13) was used for all statistical analyses. Patient ages are reported as 
medians with interquartile ranges (IQR). A proportions test was used to determine 
the difference between the proportions of patients LETM diagnosis and of the level of 
clinical myelopathy. A 2-tailed Fisher’s exact test was used to determine the 
significance of association between LETM diagnosis and I.) Clinical symmetry of 
myelopathy, II.) HIV status, III.) Cluster of differentiation 4 (CD4) count and IV.) Viral 
load.  
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Results 
LETM Diagnosis and Demographics 
The aetiology of LETM in this population was as follows: NMOSD was the most 
common diagnosis as 15 patients (68%) were diagnosed using the 2015 NMOSD 
criteria and 7 (32%) had non-NMOSD causes (p=0,0159). Among the 15 NMOSD 
patients, median age was 38 years (IQR 27-47), 14 were female, 13 were of African 
race and 2 were Caucasian. Within the 7 non-NMOSD group: 4 patients (18%) had 
an infective cause, 1 (5%) had an ischaemic myelopathy and 2 (9%) had an 
unknown or idiopathic LETM. Based on clinical, CSF and ancillary investigations, TB 
meningomyelitis was diagnosed in 3 of the 4 patients with an infective cause and 1 
patient had no identifiable infectious agent. The median age of the infective group 
was 21 years (IQR 16,5-32,5), gender was equal (2 males and 2 females) and all 4 
patients were of African race. The patient with an ischaemic myelopathy was a 62 
year old Indian male who developed an acute myelopathy after vascular surgery. 
The ischaemic LETM was confirmed by restricted diffusion on MRI. The idiopathic 
group consisted of a 49 year old female and a 19 year old male, both were of African 
race. Demyelinating, infective, neuro-inflammatory, vascular, neoplastic, 
paraneoplastic, radiation-induced and metabolic causes for LETM were excluded in 
these 2 patients diagnosed as idiopathic LETM.      
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Figure 1: LETM Diagnosis 
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Clinical presentation 
Of the 14 patients that had a cervical myelopathy, NMOSD was the most common 
cause with 13 patients (93%), and 1 patient (7%) had an infective cause (p=0,0002). 
8 patients had a thoracic myelopathy, only 2 patients (25%) were diagnosed with 
NMOSD and 6 (75%) had non-NMOSD aetiology (p=0,0455). Except the 1 patient 
with an infective cervical myelopathy, the rest of the non-NMOSD group had a 
thoracic myelopathy. The 3 patients with TB meningomyelitis presented with 
meningism in addition to their thoracic myelopathy. As expected in the NMOSD 
group, optic neuritis and brainstem syndromes were also present in various 
combinations with the LETM. The most common presentation in the NMOSD group 
was combined optic neuritis and a cervical myelopathy (7 patients). Table 1 shows 
clinically symmetrical versus asymmetrical myelopathies between the different 
diagnostic groups of LETM. A clinically asymmetrical myelopathy was much more 
common in the NMOSD patients (14/15 patients) compared to a mainly clinically 
symmetrical presentation in the infective group (3/4 patients) (p=0,016). The 
ischemic myelopathy was clinically symmetrical and both the idiopathic LETM 
patients had clinically asymmetrical myelopathies.   
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Figure 2: Clinical Presentation and LETM diagnosis 
 
Table 1: Clinical symmetry of myelopathy 
Diagnosis Symmetrical  
(no.of patients) 
Asymmetrical 
(no. of patients) 
Total 
(no. of patients) 
NMOSD 1 14 15 
INFECTIVE 3 1 4 
ISCHAEMIC 1 0 1 
IDIOPATHIC 0 2 2 
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Radiological characteristics of LETM 
The average length of the radiological LETM lesions in the total cohort was 7 
vertebral bodies. Figure 3 shows the radiological extent of the LETM into different 
regions of the spinal cord (brainstem, cervical spine, thoracic spine and conus). 2 
NMOSD patients had LETM lesions restricted to the cervical spine and 4 non-
NMOSD patients (2 infective and 2 idiopathic) had LETM lesions restricted to the 
thoracic spine. However, most patients (16 of 22) had their LETM lesions extending 
into more than 1 region of the spinal cord. However, there were no patients in this 
study that had a LETM lesion extending the entire spinal cord (brainstem to conus or 
cervical spine to conus). Table 2 displays detailed radiological characteristics of the 
LETM lesions compared to diagnosis.  Most LETM lesions (18/22 patients) caused 
expansion of the cord. Only 4 NMOSD LETM lesions showed patchy enhancement 
and all 3 TB patients displayed meningeal enhancement. Extension into the 
brainstem was seen in 11 NMOSD and 2 infective patients. Only 1 patient had a 
radiologically asymmetrical cord lesion, which corresponded with the asymmetrical 
clinical presentation.  
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Figure 3: Radiological level of LETM 
Table 2: LETM Radiological characteristics 
MRI feature NMOSD 
 (15 patients) 
INFECTION  
(4 patients) 
ISCHAEMIC  
(1 patient) 
IDIOPATHIC 
 (2 patients) 
T1 image 1 = ↑ 
3 = iso 
11 = ↓ 
 
2 =iso 
2 = ↓  
 
1 = iso 
 
2 = iso 
T2 image 15 = ↑ 4 = ↑ 1 = ↑ 2 = ↑ 
Cord 
expansion 
11 = yes 
3 = no 
1 = atrophy 
4 = yes 1 = yes 2 = yes 
Gadolinium 
enhancement 
4 = patchy  
10 = no 
1 = not done 
3 = meningeal 
1 = no  
 
 
1= not done 
2 = patchy 
T2 Axial image 12 = central 
1 = complete 
1 = asymmetrical 
1 = indeterminate 
2 = central 
 
2 = indeterminate 
 
1 = complete 
1 = central 
1 = complete 
Extension to 
brainstem 
11= yes 
3 = no 
(1 = N/A)  
2 = yes 
 
(2 = N/A) 
 
 
(1 = N/A) 
 
 
(2 = N/A) 
(Abbreviations:  ↓ = hypointense, iso = isointense, ↑ = hyperintense, N/A = not applicable as cervical cord not involved)  
0 2 4 6
T-SPINE ↔ CONUS 
T-SPINE
C-SPINE ↔ CONUS 
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HIV 
In terms of HIV status, 15 subjects were HIV negative and 7 were HIV positive. Of 
those that were HIV positive, 3 patients had TB myelitis causing LETM and 4 met 
NMOSD diagnostic criteria. HIV was more common in the infective group compared 
to the NMOSD group (75% versus 27%, p=0,117). In the HIV subgroup, CD4 counts 
were categorised into ≤200 cells/uL and >200 cells/uL, and viral loads were divided 
into ≤1000 and >1000 copies/ml. CD4 counts and viral loads were compared to 
LETM diagnosis. Lower CD4 counts were more common in the infective group and 
higher CD4 counts were seen in the NMOSD group (p=0,321). High viral load was 
associated with infective causes and low viral loads were detected in the NMOSD 
group (p=0,029). Table 2 shows the actual values of CD4 counts and viral load in the 
HIV subgroup, as well as whether highly active antiretroviral therapy (HAART) was 
being received or not at LETM onset. HAART was already initiated in 3 of the 4 
NMOSD patients compared to no HAART in the infective HIV group.  
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Figure 4: HIV status and LETM diagnosis 
 
Table 3: CD4 count and Viral load in HIV positive patients 
Diagnosis CD4 
(cells/uL) 
Viral Load 
(copies/mL) 
HAART at 
LETM onset 
NMOSD (AQ4-AB positive) 784 LDL Yes (5 years) 
NMOSD (AQ4-AB negative) 492 171 Yes (1 month) 
NMOSD (AQ4-AB negative) 503 69 No 
NMOSD (AQ4-AB positive) 202 66 Yes (3 months) 
INFECTIVE (TB) 106 287 526 No 
INFECTIVE (TB) 146 1 950 000 No 
INFECTIVE (TB) 101 690 471 No 
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HIV and NMOSD 
The NMOSD group consisted of 8 patients that were AQ4-AB positive and 7 were 
AQ4-AB negative. 4 Patients had HIV and NMOSD dual diagnoses and in all 4 
patients the HIV was confirmed before NMOSD diagnosis. These were divided into 2 
patients that were HIV positive and AQ4-AB negative, and 2 that were both HIV and 
AQ4-AB positive. Thus, no trend was seen between HIV and AQ4-AB status 
(p=1,00). 
 
 
Figure 5: HIV status and AQ4-AB in NMOSD group 
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Treatment and outcome 
NMOSD group 
At initial presentation, 6 patients responded to intravenous methylprednisolone 
(IVMP) (1gram daily for 5 days), 5 patients responded to plasma exchange (PLEX) 
(alternate days for 5 cycles), 3 patients had no response to both IVMP and PLEX 
and 1 patient did not respond to IVMP (PLEX not given). Regarding relapses; 6 
patients had no relapses, 6 patients had 1 relapse and 3 patients had 2 relapses. Of 
those with 1 relapse, treatment response at relapse was as follows: 3 responded to 
IVMP, 2 did not respond to both modalities and 1 died before relapse treatment 
could be initiated. Of the 3 patients with 2 relapses; 1 responded to PLEX at both 
relapses, 1 responded to PLEX (1st relapse) and IVMP (2nd relapse) and 1 had no 
response to treatment at both relapses. Long term treatment consisted of 10 patients 
on combined steroids and azathioprine, and 5 patients on long term steroids alone. 
At presentation of LETM, all patients had an EDSS ≥8, except 1 patient (EDSS of 5). 
Improvement in EDSS was variable with the most improvement in a patient from 9 to 
2,5. In terms of outcome, EDSS divided into ≤5; 5 ≤ 8; 8 ≤ 9,5 and 10(death), 
consisted of 3, 4, 6  and 2 patients respectively.  
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Table 4: Treatment and outcome in NMOSD group 
 
(Abbreviations: AQ4- = Aquaporin 4 antibody negative, AQ4+ = Aquaporin 4 antibody positive, HIV- = HIV 
negative, HIV+ = HIV positive, EDSS = Expanded Disability Status Scale, IVMP = intravenous 
methylprednisolone PLEX = plasma exchange, AZA = azathioprine) 
 
 
NMOSD Patient & 
AQ/HIV status 
 
Initial 
treatment 
response 
 
Relapse/s & 
treatment 
response 
 
Long term 
treatment 
 
EDSS 
at 
onset 
 
Best 
EDSS 
post-
treatment 
 
Outcome 
EDSS 
1. AQ4--/HIV- IVMP 0 AZA+Steroids 8,5 7 7 
2. AQ4+/HIV- IVMP 0 AZA+Steroids 8 7 7 
3. AQ4+/HIV- PLEX 0 AZA+Steroids 9 2,5 2,5 
4. AQ4+/HIV- NIL to both 
IVMP & PLEX 
0 AZA+Steroids 8,5 8,5 8,5 
5. AQ4+/HIV+ NIL to both 
IVMP & PLEX 
0 Steroids 8,5 8,5 8,5 
6. AQ4-/HIV+ NIL to IVMP, 
PLEX not 
given 
0 Steroids 8,5 8,5 8,5 
7. AQ4-/HIV- PLEX 1 – NIL to 
both IVMP & 
PLEX 
AZA+ 
Steroids 
9 7 9 
8. AQ4-/HIV- IVMP 1-IVMP Steroids 5 3 3 
9. AQ4+/HIV- PLEX 1 – Died 
before 
treatment 
AZA+Steroids 6 4 Died 
10. AQ4-/HIV- PLEX 1-NIL to 
both IVMP & 
PLEX 
Steroids 8,5 5 Died 
11. AQ4-/HIV- IVMP 1-IVMPl AZA+Steroids 8,5 7 7 
12. AQ4-/HIV+ IVMP 1-IVMP AZA+Steroids 9 7 7 
13. AQ4+/HIV- IVMP 1-PLEX 
2-PLEX 
AZA+Steroids 8 5 5 
14. AQ4+/HIV+ PLEX 1-PLEX 
2-IVMP 
AZA+Steroids 9 4 8,5 
15. AQ4+/HIV- NIL to both 
IVMP & PLEX 
1,2 - NIL to 
both IVMP & 
PLEX 
Steroids 9,5 9,5 9,5 
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Non-NMOSD group 
Of the 4 infective LETM patients, 3 were given anti-TB treatment with 
dexamethasone and only 1 of these patients myelopathy improved slightly (EDSS of 
8 to 7) and the other 2 TB patients remained with a EDSS of 8. The other 1 patient 
with an infective LETM received ceftriaxone and a solumedrol pulse and improved 
significantly (EDSS of 8,5 to 4). The patient with the ischaemic LETM did not 
respond to a solumedrol pulse and died 2 months after onset due to systemic 
complications. In the idiopathic LETM group, 1 patient responded to a solumedrol 
pulse (EDSS of 7 to 4) and was put on a steroid taper. The other patient with 
idiopathic LETM did not respond to a solumedrol pulse, however, a response to 
PLEX was seen (EDSS of 8 to 5).   
 
Discussion 
In keeping with the literature, NMOSD was the most common cause of LETM in this 
study. The age of patients and dominant female gender is also similar to the reported 
NMOSD demographics.5 The majority of patients in the NMOSD group were of 
African race and this is may be due to the background population, however, there 
has been suggestions that NMOSD may be more prevalent in the black 
population.6,7 The infective group consisted of only 4 patients and this may have 
been under-represented in this study as some infective LETM patients may be 
treated by infectious disease specialists or general physicians and are possibly not 
always referred to neurology. The median age was much younger in the infective 
group compared to the NMOSD group (21 versus 38 years) and thus age may direct 
diagnosis. The clinical context of the LETM also guides diagnosis as the ischaemic 
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myelopathy was suspected due to an acute onset after vascular surgery and the TB 
LETM patients had meningism and suggestive cerebrospinal fluid (CSF) results. 
The level of myelopathy in determining the underlying aetiology was of clinical and 
statistical significance. The NMOSD group had a strong predilection for the cervical 
cord and almost all the non-NMOSD patients affected the thoracic cord. NMOSD is 
known to affect predominantly the upper cord and extend into the dorsal medulla.3,4 
This was represented in this cohort and correlated radiologically as 14 NMOSD 
patients had cervical involvement on MRI and 11 of these extended into the medulla. 
The fact that no lesion involved the entire cord further emphasizes a specific 
anatomical preference of the LETM lesion. Most NMOSD patients (14/15) presented 
with a clinically asymmetrical myelopathy, in contrast to typical descriptions of 
NMOSD causing a complete myelopathy.3 This is a challenge to explain as only 1 of 
these patients had an asymmetrical radiological lesion on axial images, the rest were 
symmetrical (complete or central). This clinico-radiological discrepancy is not well 
described yet was a noteworthy result in this cohort.  
The idiopathic group showed features of NMOSD in this study as they were both 
clinically asymmetrical but involved the thoracic cord which is not in keeping with 
typical NMOSD. These 2 patients may represent the myelin oligodendrocyte 
glycoprotein-antibody (MOG-AB) NMOSD subtype which has been reported to affect 
more males, involve the lower cord and have a milder phenotype.3,17 Unfortunately, 
MOG-AB testing was not available and may also have been of benefit in testing the 
AQ4-AB negative NMOSD patients.  A tissue-based assay was used to test for AQ4-
AB which has a sensitivity and specificity of about 60% and 98% respectively.18 Thus 
the idiopathic and AQ4-AB negative NMOSD patients may have had false negative 
AQ4-AB tests and using a more sensitive assay may have revealed more accurate 
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results. The idiopathic LETM patients could represent a separate disease entity 
which has been described within the literature.19 
Despite a high HIV prevalence in our population, most of the LETM cohort was HIV 
negative. The HIV positive patients made up most of the infective group and were a 
minority in the NMOSD group. This is not surprising as HIV predisposes to 
opportunistic infections and it is uncommonly associated with NMOSD.9-12 The CD4 
count and viral load may direct an underlying cause as the infective group had low 
CD4 counts with high viral load and the NMOSD group had high CD4 counts with 
low viral load. Viral load as a predictor of diagnosis was found to be statistically 
significant. Interestingly, 1 patient was diagnosed with HIV and pulmonary TB 4 
months before being diagnosed with NMOSD (AQ4-AB positive). This may represent 
activation of NMOSD by pulmonary TB which has been described in the literature.2,15  
Treatment responses were variable in the NMOSD group. Responses were also 
inconsistent as some patients responded to different therapies during relapse/s or 
did not respond at all to a therapy that was initially beneficial. Thus, a reasonable 
approach in acute therapy is to use IVMP as 1st line treatment, irrespective of 
previous response, and use PLEX as 2nd line therapy. Some patients relapsed 
despite being on long-term immunosuppression but this may have been due to 
suboptimal dosing and compliance issues. LETM was associated with a high 
morbidity and mortality as only 4 patients had an EDSS <5 and 3 patients died.  
The major limitation of this study was small sample size. The study was conducted 
over approximately 2 years and patient follow up was variable and relatively short 
compared to the chronicity of this syndrome.  
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Conclusion   
NMOSD is a common cause of LETM and is suggested by cervical involvement 
compared to a thoracic LETM which suggests non-NMOSD causes. In HIV positive 
patients with LETM, NMOSD is less likely and alternative diagnoses should be 
excluded, especially infective causes. Nevertheless, NMOSD occurs in HIV positive 
patients and may be associated with a low viral load.  
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Chapter 3: Appendix 
I. Data collection sheet  
 
1. DEMOGRAPHICS 
Study No. 
Age 
Sex 
Race 
 
2. FIRST PRESENTATION 
History 
 
 
 
 
 
 
 
 
 
 
 
- Previous myelitis/optic neuritis 
- Comorbidities 
- Family History 
Examination 
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3. INVESTIGATIONS 
ANTI AQUAPORIN 4 Ab: 
HIV: 
SERUM 
INFLAMMATORY AUTOIMMUNE METABOLIC ENDOCRINE 
CRP 
ESR 
Serum ACE 
Syphilis 
ANA 
Anti SM ab 
Anti RNP 
Anti Ro 
Anti La 
RF 
Vitamin B12 
Copper 
Caeruloplasmin 
TSH 
 
CSF       MRI 
Prot 
Glucose 
Poly 
Lymph 
RBC 
Culture 
Syphilis 
Other Investigations 
 
 
 
 
4. DIAGNOSIS: 
5. TREATMENT & FOLLOW-UP 
 
 
 
BRAIN 
SPINE 
- Level of cord 
- Length 
- T1 
- T2 
- Gadolinium 
- Axial 
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II. Ethics Clearance Certificate 
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III. Plagiarism Report  
 
